By Sneha S K and Sahil Pandey<\/p>\n
Dec 31 (Reuters) – The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics’ drug for the \u200btreatment of a rare hormonal disorder, the company said on Wednesday.<\/p>\n
Shares \u200cof the drugmaker were down 48% at $36.41.<\/p>\n
The company said the FDA could not arrive at a \u200cfavorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.<\/p>\n
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.<\/p>\n
“FDA’s request for additional data may require \u2060additional trials, significantly dimming Corcept’s \u200coutlook in Cushings,” said Truist analyst Joon Lee.<\/p>\n
Hypercortisolism, also known as Cushing’s syndrome, occurs when the body is exposed to \u200dhigh cortisol activity.<\/p>\n
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism’s signs and symptoms.<\/p>\n
“We will meet with the FDA as soon \u200bas possible to discuss the best path forward,” said Joseph Belanoff, Corcept’s \u200cCEO.<\/p>\n
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing’s also experience diabetes, high blood pressure, muscle weakness and immune suppression.<\/p>\n
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain \u2060off\u2011target hormonal effects.<\/p>\n
“Given the company had opportunities \u200bto address FDA’s concerns during mid and late-stage \u200breviews, it’s unclear if any further dialogue can resolve the review issues without additional trials,” Lee added.<\/p>\n
Corcept is also studying the \u200ddrug in a variety \u2060of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by \u2060hypercortisolism in adults with endogenous Cushing’s syndrome.<\/p>\n
Other approved treatments for Cushing’s syndrome include Isturisa by Recordati \u200cand Xeris Biopharma’s Recorlev.<\/p>\n
(Reporting by Sahil Pandey and Sneha S \u200cK in Bengaluru; Editing by Shailesh Kuber)<\/p>\n","protected":false},"excerpt":{"rendered":"By Sneha S K and Sahil Pandey Dec 31 (Reuters) – The U.S. Food and Drug Administration has…\n","protected":false},"author":3,"featured_media":486627,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[218767,219787,6434,210,32108,218768,219788,1060,67,132,68],"class_list":["post-486626","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-corcept-therapeutics","tag-cushing39s-syndrome","tag-food-and-drug-administration","tag-health","tag-hormonal-disorder","tag-hypercortisolism","tag-joon-lee","tag-medication","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115824411502032586","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/486626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=486626"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/486626\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/486627"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=486626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=486626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=486626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}